GSK3B and osteosarcoma: Moreover, to validate the anti-osteosarcoma effect is achieved specifically via cantharidin-caused Wnt/β-catenin signaling inactivation; we pretreated 143B cells using specific GSK-3β inhibitor (CHIR99021) before being challenged using 2.5 μM cantharidin.